
|Articles|December 1, 2003
Drug combo reduces PSA in high-risk PCa patients
Portland, OR-Weekly preoperative chemotherapy with docetaxel (Taxotere)and mitoxantrone (Novantrone) reduced PSA levels and was associated witha high rate of negative surgical margins in a small preliminary clinicaltrial involving high-risk localized prostate cancer patients.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
Optimizing care for men with overactive bladder, with Keith Xavier, MD
4
The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson, II, MD, MPH
5






